Hematologia (Hematology): Five Thinks to Know About Online

 

–  A série Five Thinks to Know About – do Canadian Medical Association Journal, traz pontos-chave de diferentes temas médicos, abordando desde o diagnóstico, tratamento e as recomendações especiais sobre uma condição clínica

– Iniciaremos com três importantes temas no campo da Hematologia: Treating iron deficiency, Myelodysplatic syndrome and Direct oral anticoagulants and the bleedings patients

– Acesse o link para o texto completo original, com imagens e comentários

 

Treating iron deficiency

– Treating iron deficiency begins with addressing the cause

– Oral iron replacement is first-line therapy

– Supplement selection depends on elemental iron dose, tolerability and cost

– Intravenous iron is second-line therapy

– Dosing of intravenous iron depends on the patient´s iron deficit

■ Treating iron deficiency

M P Zeller, M Verhovsek

CMAJ 2017, vol 189 (10): E409

http://www.cmaj.ca/content/187/14/1074

 

Myelodysplastic syndrome

– Myleodysplastic syndrome is a disease of older adults and is becoming more common

– Myelodysplastic syndrome commonly presents as fatigue

– Myelodysplastic syndrome should be suspected in older patits with macrocytic anemia

– Patients with unexplained severe or progressive cytopenia should be referred to a hematologist

– Active treatment is available and improves outcomes in myelodysplastic syndrome

■ Myelodysplastic syndrome

R A Wells, R Buckstein, J Rezmovitz

CMAJ 2016, vol 188 (10): 751

http://www.cmaj.ca/content/188/10/751

 

Direct oral anticoagulants and the bleeding patients

– Direct oral anticoagulant agents are now routinely used for the prevention of stroke in nonvalvular atrial fibrillation

– Risk of bleeding with direct oral anticoagulants is lower than with vitamin K antagonists, but varies by site

– Direct oral anticoagulants are characterized by rapid onset of action and short half-live

– Direct oral anticoagulants variably affect standard clot-based assays

– Idarucizumab has recently been approved by the US Food and Drug Adminstration to reverse the activity of dabigatran

 

■ Direct oral anticoagulants and the bleeding patient

B Wood, M Sholberg, A Ackery

CMAJ 2016, vol 188 (3): 215

http://www.cmaj.ca/content/188/3/215

 

by Dr Paulo Fernando Leite

■ Cardiologia/Prevenção Cardiovascular

■ Estratificação de Risco Cardiovascular

Av Contorno 8351 – Conj 01

Belo Horizonte/MG/Brasil

Tel: 31 32919216    2917003    3357229

(- consulta particular –)

CRMMG: 7026

Email: pfleite1873@gmail.com